HC Wainwright Predicts Genelux's Q1 Earnings (NASDAQ:GNLX)

Genelux Co. (NASDAQ:GNLX - Free Report) - Equities research analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for Genelux in a note issued to investors on Monday, March 31st. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.25) for the quarter, down from their previous estimate of ($0.16). HC Wainwright has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Genelux's current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux's Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($0.76) EPS, FY2028 earnings at $0.32 EPS and FY2029 earnings at $1.32 EPS.

Genelux (NASDAQ:GNLX - Get Free Report) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09).

Genelux Trading Up 1.6 %

Shares of NASDAQ:GNLX traded up $0.04 during trading on Thursday, reaching $2.20. The company had a trading volume of 84,549 shares, compared to its average volume of 233,283. The company has a fifty day moving average of $3.96 and a two-hundred day moving average of $3.10. The stock has a market capitalization of $75.96 million, a P/E ratio of -2.36 and a beta of -0.36. Genelux has a 12 month low of $1.60 and a 12 month high of $5.89.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in shares of Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company's stock worth $749,000 after purchasing an additional 89,854 shares in the last quarter. Marshall Wace LLP boosted its stake in Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock worth $368,000 after buying an additional 52,958 shares in the last quarter. LPL Financial LLC boosted its stake in Genelux by 72.3% in the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company's stock worth $222,000 after buying an additional 39,516 shares in the last quarter. XTX Topco Ltd bought a new position in Genelux during the third quarter valued at approximately $59,000. Finally, D.A. Davidson & CO. purchased a new position in shares of Genelux during the fourth quarter worth approximately $51,000. Institutional investors own 37.33% of the company's stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.